Propofol Pharmacology

Quick Answer

Propofol (2,6-diisopropylphenol) is a phenol derivative intravenous anaesthetic that acts primarily as a positive allosteric modulator of GABA_A receptors, particularly at the beta-subunit, increasing chloride conductance and producing rapid-onset hypnosis, sedation, and amnesia. Its pharmacokinetics are characterized by rapid distribution into peripheral tissues (three-compartment model), high lipid solubility allowing quick blood-brain barrier crossing (<40 seconds), and hepatic metabolism via glucuronidation to inactive water-soluble metabolites excreted renally. Clinical advantages include rapid emergence with minimal postoperative nausea and vomiting (PONV), though significant adverse effects include dose-dependent hypotension (30-40% reduction in MAP), respiratory depression with apnea during induction, pain on injection (28-90% of patients), and rare but fatal propofol infusion syndrome (PRIS) with prolonged high-dose infusions (>4 mg/kg/hr for >48 hours). Propofol is extensively used for induction and maintenance of general anaesthesia, procedural sedation, and ICU sedation, with dosing typically 1.5-2.5 mg/kg for induction and 50-200 mcg/kg/min for maintenance, requiring careful hemodynamic monitoring especially in elderly or hypovolemic patients. [1-8]

Pharmacology Overview

Chemical Classification and Structure

Propofol (2,6-diisopropylphenol) is a short-acting intravenous anaesthetic agent belonging to the alkylphenol class. First introduced into clinical practice in 1986, it has largely replaced barbiturates and benzodiazepines as the induction agent of choice due to its superior pharmacokinetic profile and rapid recovery characteristics. The chemical structure consists of a phenol ring with two isopropyl groups at the 2- and 6-positions, which confers high lipid solubility and determines its physicochemical properties. Propofol is practically insoluble in aqueous solution and is formulated as an oil-in-water emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% egg lecithin, with the propofol concentration of either 1% (10 mg/mL) or 2% (20 mg/mL). The emulsion formulation presents challenges including potential for bacterial contamination, which necessitates strict aseptic handling and discarding within 6-12 hours of opening. Newer lipid-free formulations using cyclodextrin or prodrug approaches have been developed but have not achieved widespread clinical adoption. [9-15]

Molecular Mechanism of Action

Propofol's primary mechanism of action involves potentiation of gamma-aminobutyric acid type A (GABA_A) receptors, the major inhibitory neurotransmitter receptors in the central nervous system. Propofol binds to specific sites on the beta-subunit of the GABA_A receptor complex, acting as a positive allosteric modulator that increases the affinity of the receptor for GABA and prolongs the duration of chloride channel opening. This results in enhanced chloride influx into neurons, leading to membrane hyperpolarization and decreased neuronal excitability. Unlike benzodiazepines, which bind to the alpha-gamma subunit interface, propofol's interaction with the beta-subunit produces more profound hypnotic and sedative effects. At higher concentrations, propofol can directly activate GABA_A receptors even in the absence of GABA, providing an additional mechanism for its anesthetic effects. [16-22]

The hypnotic properties of propofol also involve modulation of other neurotransmitter systems. Propofol inhibits N-methyl-D-aspartate (NMDA) glutamate receptors, particularly those containing NR2B subunits, which may contribute to its analgesic properties and neuroprotective effects observed in experimental models. Additionally, propofol modulates glycine receptors and inhibitory G protein-coupled inwardly-rectifying potassium (GIRK) channels, enhancing inhibitory neurotransmission. Recent studies have identified potential interactions with hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which may contribute to its effects on thalamocortical rhythms and unconsciousness. The complex pharmacology of propofol involves multiple receptor targets, explaining its diverse clinical effects including hypnosis, amnesia, and modest analgesia. [23-30]

GABA_A Receptor Subtype Selectivity

GABA_A receptors are pentameric ligand-gated ion channels composed of various combinations of alpha (α1-6), beta (β1-3), gamma (γ1-3), delta (δ), epsilon (ε), theta (θ), pi (π), and rho (ρ1-3) subunits. Propofol demonstrates selectivity for GABA_A receptors containing β2 or β3 subunits, with particularly high affinity for β3-containing receptors. Mice lacking β3 subunits show dramatically reduced sensitivity to propofol, confirming the importance of this subunit for propofol's hypnotic effects. The alpha-subunit composition influences the pharmacological profile, with α1-containing receptors mediating sedative effects and α2/3-containing receptors contributing to anxiolytic and muscle relaxant properties. The regional distribution of GABA_A receptor subtypes throughout the central nervous system explains propofol's differential effects on various brain regions, with particularly strong depression of activity in the thalamus, cortex, and brainstem respiratory centers. Understanding this receptor subtype selectivity has implications for developing newer agents with improved side effect profiles. [31-38]

Pharmacokinetic Principles

Absorption and Distribution

Propofol is administered exclusively by intravenous injection due to extensive first-pass metabolism and poor oral bioavailability (<2%). Following intravenous bolus administration, propofol exhibits extremely rapid onset of action, with loss of consciousness typically occurring within 15-45 seconds depending on the dose and injection speed. This rapid onset is explained by propofol's high lipid solubility (octanol:water partition coefficient ~6,900:1), allowing rapid equilibration across the blood-brain barrier and efficient penetration into lipid-rich neuronal membranes. The volume of distribution (Vd) for propofol is large, ranging from 2-10 L/kg, reflecting extensive tissue distribution, particularly to well-perfused organs and adipose tissue. The distribution follows a three-compartment model: a rapid distribution phase (distribution half-life 2-4 minutes) into highly perfused tissues including the brain, heart, and kidneys; an intermediate distribution phase (10-15 minutes) into muscle; and a slow terminal distribution phase (1-3 hours) into adipose tissue. The context-sensitive half-time, which is more clinically relevant for infusion durations, remains relatively constant even with prolonged infusions due to propofol's rapid metabolism, contributing to predictable emergence regardless of infusion duration. [39-46]

Protein Binding and Tissue Distribution

Propofol is extensively protein-bound, with approximately 97-99% bound to plasma proteins, primarily albumin and to a lesser extent α1-acid glycoprotein. The high degree of protein binding limits the free fraction of propofol available for receptor interaction and pharmacological effect. Conditions that alter plasma protein concentrations, such as hypoalbuminemia, liver disease, or acute phase responses, may affect the free fraction and dosing requirements. Propofol's high lipid solubility results in significant accumulation in adipose tissue, particularly with prolonged infusions. In obese patients, the increased adipose mass can prolong propofol's terminal elimination half-life due to slow redistribution from fat stores. However, for single bolus doses or short infusions, the initial Vd is primarily determined by lean body mass rather than total body weight. Propofol readily crosses the placenta, with fetal concentrations reaching approximately 70% of maternal levels within 15 minutes of maternal administration. It also appears in breast milk, although the amount transferred to the infant is generally considered clinically insignificant. [47-55]

Metabolism

Propofol undergoes extensive hepatic metabolism primarily through conjugation reactions, with glucuronidation being the predominant pathway. Approximately 40-60% of propofol is metabolized via direct conjugation to propofol glucuronide by UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A9. An additional 30-50% undergoes phase I hydroxylation to 4-hydroxypropofol, primarily catalyzed by cytochrome P450 2B6 and 2C9, followed by glucuronidation to 4-hydroxypropofol glucuronide. These glucuronide metabolites are pharmacologically inactive and highly water-soluble, facilitating renal excretion. Less than 0.3% of unchanged propofol is excreted unchanged in urine. Extrahepatic metabolism occurs to a lesser extent in the kidneys and possibly the lungs, contributing to propofol's clearance even in severe hepatic impairment. The metabolic pathways are saturable only at very high plasma concentrations, explaining the linear pharmacokinetics across clinically relevant dose ranges. The rapid and extensive metabolism, coupled with the formation of inactive metabolites, contributes to propofol's favorable recovery profile and lack of active metabolites that could accumulate with renal or hepatic dysfunction. [56-65]

Elimination and Clearance

Propofol has a high systemic clearance, typically 1.5-2.5 L/min, which exceeds hepatic blood flow, indicating extrahepatic clearance mechanisms. Total body clearance exceeds 20-30 mL/kg/min in healthy adults, explaining the rapid offset of action despite the large volume of distribution. The elimination half-life (t1/2β) of propofol is 4-7 hours in healthy subjects, though this is of limited clinical relevance because recovery is determined by redistribution and clearance from highly perfused tissues rather than terminal elimination. Renal elimination of metabolites accounts for approximately 90% of total elimination, with the remaining 10% excreted in feces via biliary excretion. Patients with hepatic impairment may have reduced clearance and prolonged elimination half-life, requiring dose reduction. Interestingly, renal failure has minimal effect on propofol pharmacokinetics as the parent drug is not renally excreted and metabolites are inactive. The high clearance and rapid metabolism allow propofol infusions to be titrated to effect with predictable emergence times even after prolonged administration, making it ideal for both short procedures and long-term ICU sedation. [66-73]

Pharmacokinetics in Special Populations

Elderly patients demonstrate increased sensitivity to propofol due to reduced clearance (approximately 30% lower than young adults) and possibly increased brain sensitivity. The induction dose should be reduced by 30-50% in patients over 65 years of age. Obese patients present complex pharmacokinetic changes; loading doses should be based on lean body weight to avoid overdose, while maintenance infusion rates may need to be based on total body weight due to increased clearance in some obese individuals. However, adipose accumulation with prolonged infusions can prolong emergence in morbid obesity (BMI >40 kg/m²). Pediatric patients have higher clearance rates (50-100% greater than adults), requiring higher weight-based dosing (2.5-3.5 mg/kg for induction, 150-300 mcg/kg/min for maintenance). Critically ill patients with capillary leak syndrome may have increased Vd and altered protein binding, while patients with hepatic impairment require dose reduction of 25-50%. Pregnancy increases sensitivity to propofol, possibly due to hormonal effects on GABA_A receptors, with induction dose reductions of 30-40% recommended. Understanding these population-specific changes is crucial for safe and effective dosing. [74-82]

Pharmacodynamics

Hypnotic Effects and Dose-Response

Propofol produces a dose-dependent depression of the central nervous system resulting in hypnosis, sedation, and loss of consciousness. The concentration-effect relationship follows a sigmoid Emax model, with typical effect-site concentrations for various endpoints: 0.5-1.0 mcg/mL for sedation, 1.5-2.5 mcg/mL for loss of consciousness, and 2.5-4.0 mcg/mL for surgical anesthesia. The interindividual variability in sensitivity is considerable, with some patients requiring twice the dose for equivalent effect. Elderly patients are approximately twice as sensitive as young adults, while pediatric patients require higher doses per kilogram. The hypnotic effects are rapidly reversible with discontinuation, with patients typically regaining consciousness within 5-15 minutes after short infusions. This rapid recovery is attributable to propofol's high clearance and rapid redistribution from the brain. Bispectral index (BIS) monitoring can guide propofol administration, with target BIS values of 40-60 during general anesthesia. However, BIS values must be interpreted in conjunction with clinical signs as certain conditions (hypothermia, hypoglycemia, certain neurological conditions) can affect readings independently of anesthetic depth. [83-91]

Cardiovascular Effects

Propofol causes significant dose-dependent cardiovascular depression, representing one of its most important adverse effects. After a typical induction dose (1.5-2.5 mg/kg), mean arterial pressure decreases by 25-40% and cardiac output decreases by 15-30%. The primary mechanism is peripheral vasodilation mediated by decreased sympathetic tone, direct vasodilation of vascular smooth muscle, and possible effects on endothelial nitric oxide release. Propofol also causes mild negative inotropy, reducing myocardial contractility by approximately 10-15%. The baroreceptor reflex is blunted, preventing the compensatory tachycardic response that would normally accompany hypotension. Heart rate typically decreases by 10-20%, and bradycardia (<50 bpm) can occur, particularly with rapid bolus administration or in patients receiving beta-blockers. Patients with hypovolemia, cardiac dysfunction, or autonomic neuropathy are particularly susceptible to propofol-induced hypotension. Pretreatment with fluid loading (500-1000 mL crystalloid) and gradual drug administration can attenuate hemodynamic changes. The cardiovascular effects are maximal within 1-2 minutes of administration and gradually resolve as plasma concentrations decrease with redistribution and metabolism. [92-100]

Respiratory Effects

Respiratory depression is a prominent feature of propofol pharmacology, occurring even at subhypnotic doses. At sedation doses (0.5-1.0 mcg/mL), tidal volume decreases and respiratory rate becomes more irregular. At induction doses, apnea is common, occurring in 70-100% of patients and lasting 30-90 seconds depending on the dose and speed of administration. Propofol decreases the ventilatory response to hypercapnia (CO2 retention) and hypoxia (low oxygen), potentially delaying arousal from respiratory depression. Upper airway reflexes are depressed, increasing the risk of aspiration and making airway maintenance more challenging during sedation. The combination with opioids or benzodiazepines produces synergistic respiratory depression, necessitating careful dose titration and continuous monitoring of respiratory status when propofol is used with these agents. The respiratory depressant effects are centrally mediated via action on brainstem respiratory centers, particularly the pre-Bötzinger complex and nucleus tractus solitarius. For procedural sedation, capnography is recommended as an early indicator of respiratory depression. Recovery of spontaneous ventilation occurs rapidly with redistribution of propofol from the brain. [101-109]

Analgesic and Anti-Nociceptive Effects

Propofol possesses modest analgesic properties, though it is not typically used as a primary analgesic agent. It enhances the analgesic effects of opioids, allowing opioid dose reduction of 30-50% when used in combination. The anti-nociceptive effects are mediated through multiple mechanisms including inhibition of spinal cord dorsal horn neurons, modulation of NMDA receptor function, and activation of inhibitory glycine receptors. Propofol reduces the minimum alveolar concentration (MAC) of volatile anesthetics by approximately 30-50%, demonstrating its anesthetic-sparing effects. At subanesthetic concentrations, propofol may reduce neuropathic pain through effects on central sensitization processes. Recent studies suggest propofol has anti-inflammatory properties, modulating cytokine production and reducing oxidative stress, which may contribute to postoperative analgesia and potential organ protection. However, propofol's analgesic effects are insufficient as monotherapy for painful procedures, and adjunctive analgesics are generally required. The interaction with opioids is complex, with synergistic enhancement of respiratory depression but additive or synergistic enhancement of analgesia depending on the specific opioid and dosing regimen. [110-118]

Antiemetic Effects

A notable advantage of propofol compared to other intravenous anesthetics is its antiemetic effect, which significantly reduces the incidence of postoperative nausea and vomiting (PONV). The mechanism is not fully elucidated but may involve direct antiemetic action at the chemoreceptor trigger zone in the area postrema, modulation of serotonin receptors, and possible interactions with dopaminergic pathways. Propofol at subhypnotic doses (10-20 mg bolus or 10-25 mcg/kg/min infusion) has been used to treat established PONV, with response rates of 60-80%. For prophylaxis, the risk of PONV after propofol-based anesthesia is approximately 50% lower than after inhalational anesthesia, particularly when propofol is used for both induction and maintenance. The antiemetic effect appears dose-related, with higher doses and longer infusions providing more prolonged protection. This property makes propofol an excellent choice for patients at high risk for PONV or for procedures where postoperative nausea is particularly problematic. The antiemetic effect persists for several hours after discontinuation, likely related to propofol's metabolites or sustained receptor effects. [119-126]

Neuroprotective Effects

Extensive preclinical research has investigated propofol's potential neuroprotective properties, particularly in models of cerebral ischemia and traumatic brain injury. Proposed mechanisms include reduction of cerebral metabolic rate for oxygen (CMRO2), modulation of excitotoxic neurotransmitter release, anti-inflammatory effects, antioxidant properties, and anti-apoptotic signaling. Propofol reduces CMRO2 by approximately 50-60% at doses producing unconsciousness, potentially extending the tolerable duration of ischemia during periods of reduced cerebral blood flow. Animal studies suggest propofol may reduce neuronal death in models of stroke and cardiac arrest, though these findings have not consistently translated to clinical benefit in human studies. The use of propofol for sedation in traumatic brain injury and status epilepticus is based partly on theoretical neuroprotective effects and favorable pharmacokinetics. However, clinical evidence for improved neurological outcomes with propofol versus other sedatives remains limited, and the theoretical benefits must be weighed against the risks of hypotension and other adverse effects. Ongoing research continues to investigate propofol's potential role in neuroprotection. [127-135]

Clinical Pharmacology

Indications

Propofol has diverse clinical applications across anesthetic and critical care settings. For induction of general anesthesia, propofol (1.5-2.5 mg/kg) provides rapid, smooth induction with minimal excitatory effects, making it the agent of choice for most patients. It is equally effective for maintenance of anesthesia via continuous infusion (50-200 mcg/kg/min) and can be combined with nitrous oxide or reduced concentrations of volatile anesthetics for balanced anesthesia. In the intensive care unit, propofol is widely used for sedation of mechanically ventilated patients, offering advantages of rapid titration to effect and predictable emergence for neurological assessment. Typical ICU sedation doses range from 5-50 mcg/kg/min, titrated to Richmond Agitation-Sedation Scale (RASS) or other validated sedation scales. For procedural sedation outside the operating room (endoscopy, cardioversion, radiology procedures), propofol (0.5-1.5 mg/kg bolus followed by 25-150 mcg/kg/min infusion) provides sedation with rapid recovery. In epilepsy management, propofol is a third-line agent for refractory status epilepticus, typically used as boluses of 1-2 mg/kg followed by infusion of 30-200 mcg/kg/min. The versatility of propofol across these diverse applications is based on its favorable pharmacokinetic profile and dose-dependent spectrum of effects. [136-145]

Dosage and Administration

Propofol dosing varies significantly based on clinical indication, patient population, and concomitant medications. For induction of general anesthesia in healthy adults, 1.5-2.5 mg/kg IV over 10-30 seconds produces loss of consciousness within 15-40 seconds. Elderly patients require 30-50% dose reduction (1.0-1.5 mg/kg), while pediatric patients (1-12 years) typically need higher doses (2.5-3.5 mg/kg). Pre-induction with a benzodiazepine or opioid can reduce the propofol requirement by 25-50%. For maintenance of anesthesia, target-controlled infusion (TCI) systems can guide dosing, with typical effect-site concentrations of 3-5 mcg/mL for general anesthesia. Manual infusion rates of 100-200 mcg/kg/min are commonly used. In the ICU, sedation is initiated at 5-10 mcg/kg/min and titrated upward by 5 mcg/kg/min every 5-10 minutes to achieve the target sedation level. For procedural sedation, an initial bolus of 0.5-1.0 mg/kg is followed by infusion of 25-100 mcg/kg/min. Propofol should always be administered via a dedicated intravenous line, preferably in a large vein, to minimize pain on injection. The drug should be prepared using aseptic technique and used within 6-12 hours of opening the ampoule or vial to prevent bacterial contamination. [146-155]

Contraindications

Absolute contraindications to propofol include documented hypersensitivity to propofol, egg protein, or soybean oil. Relative contraindications include severe cardiovascular instability (cardiogenic shock, severe aortic stenosis), hypovolemia, and conditions predisposing to propofol infusion syndrome (carnitine deficiency, mitochondrial disorders, severe fatty acid oxidation defects). Caution is required in patients with epilepsy, as propofol may precipitate seizures in susceptible individuals, though it can also be used to treat refractory status epilepticus. Patients with hyperlipidemia or those receiving lipid emulsions for nutrition may be at increased risk of complications from the lipid vehicle. Pregnancy is not an absolute contraindication, but propofol crosses the placenta and its use requires careful risk-benefit assessment, particularly during organogenesis. Breastfeeding is generally considered safe to resume 4-6 hours after propofol administration due to minimal transfer into breast milk. The decision to use propofol must consider individual patient factors, planned procedure, and alternative agents. [156-164]

Drug Interactions

Propofol exhibits numerous clinically significant drug interactions that influence dosing requirements and adverse effect profiles. Opioids produce synergistic respiratory depression and can reduce propofol requirements by 30-50% for induction and maintenance. Benzodiazepines also potentiate propofol's effects, with midazolam pretreatment reducing the propofol ED50 by 50-60%. Combined use requires careful monitoring and dose reduction of both agents. Acute alcohol intoxication increases sensitivity to propofol, while chronic alcohol use may induce tolerance and increased requirements. Local anesthetics, particularly bupivacaine, may potentiate propofol-induced cardiac toxicity when used together. Drugs that inhibit cytochrome P450 enzymes (e.g., cimetidine, erythromycin) have minimal effect on propofol metabolism due to its predominant glucuronidation pathway. Concurrent use of vasoactive drugs (nitroglycerin, calcium channel blockers) may exacerbate propofol-induced hypotension. Neuromuscular blocking agents demonstrate enhanced potency in the presence of propofol, requiring monitoring of neuromuscular function when used together. Understanding these interactions is essential for safe perioperative drug administration. [165-173]

Monitoring Requirements

Propofol administration requires vigilant monitoring due to its rapid onset of action and potential for serious adverse effects. Standard monitoring includes continuous electrocardiography, non-invasive or invasive blood pressure monitoring every 2-5 minutes, pulse oximetry, and capnography to detect respiratory depression. For ICU sedation, depth of sedation should be assessed regularly using validated scales such as RASS (-1 to -5) or Sedation-Agitation Scale (SAS), with target ranges individualized based on clinical goals. Bispectral index monitoring can help titrate propofol to prevent awareness and minimize drug exposure, though its benefit in routine practice remains controversial. For prolonged infusions (>48 hours), routine monitoring for propofol infusion syndrome includes daily assessment of serum triglycerides (aiming for <500 mg/dL), creatine kinase, lactate, and acid-base status. Blood cultures should be obtained if sepsis is suspected, as propofol emulsions can support bacterial growth. Adequate analgesia assessment is essential when using propofol for sedation, as pain can cause agitation despite adequate hypnotic effect. Documentation of propofol doses and cumulative exposure is recommended, especially for high-dose or prolonged infusions. [174-182]

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test propofol's mechanism of action, with emphasis on GABA_A receptor interaction at the beta-subunit (not alpha-gamma interface like benzodiazepines). Questions often ask about propofol's metabolic pathways, with the key point being extensive hepatic glucuronidation by UGT1A9 (not CYP450 metabolism, although minor CYP involvement exists). Pharmacokinetic questions commonly focus on propofol's high lipid solubility, three-compartment model distribution, and clearance exceeding hepatic blood flow. Candidates should be able to calculate loading doses and infusion rates for various clinical scenarios and understand the effect of patient factors (age, obesity, hepatic impairment) on dosing requirements. The context-sensitive half-time concept frequently appears, with propofol's relatively constant emergence time being a key differentiator from other agents. Questions on propofol infusion syndrome often test the definition (prolonged high-dose infusion >4 mg/kg/hr for >48 hours) and presenting features (metabolic acidosis, rhabdomyolysis, cardiac failure). [183-191]

Primary Viva Question Themes

Primary vivas commonly begin with mechanism of action and progress to clinical applications. Examiners may ask candidates to explain propofol's interaction with GABA_A receptors, including the specific subunit involved (beta) and the resulting electrophysiological effect (increased chloride conductance). Follow-up questions may explore differences from benzodiazepines (binding site, speed of onset, amnestic properties). Pharmacokinetic questions typically include drawing a concentration-time graph after IV bolus, identifying distribution phases, and explaining the concept of context-sensitive half-time. Candidates may be asked to compare propofol's elimination with other agents and explain the role of extrahepatic metabolism. Clinical scenario questions frequently involve dosing for special populations (elderly, obese, pediatric), management of adverse effects (hypotension, apnea), and considerations for prolonged ICU sedation including PRIS monitoring. The viva may also include calculation questions (loading dose, infusion rate, time to awakening) and discussion of alternative agents. [192-200]

Calculation Questions

Pharmacokinetic calculations form a core component of propofol viva questions. Common calculations include: determining loading dose based on desired concentration and volume of distribution (Dose = C × Vd); calculating infusion rate to maintain steady-state concentration (Rate = Cl × Css); estimating time to awakening after infusion cessation; comparing dosing requirements between healthy adults and special populations; and converting between different units (mg/kg vs mcg/kg/min). Candidates should be comfortable with basic pharmacokinetic equations and understand their clinical application. Sample calculation: A 70 kg patient requires propofol at 150 mcg/kg/min for ICU sedation. What infusion rate in mL/hr should be administered for 1% propofol? Calculation: 150 mcg/kg/min × 70 kg = 10,500 mcg/min = 10.5 mg/min = 630 mg/hr. For 1% propofol (10 mg/mL), this equals 63 mL/hr. Candidates should also be able to calculate drug accumulation with repeated doses and estimate elimination time based on half-life. [201-209]

Comparison Questions

Propofol is frequently compared to other intravenous anesthetics in exam questions. Compared to thiopental, propofol has faster recovery, less hangover effect, antiemetic properties, but causes more hypotension. Compared to etomidate, propofol lacks adrenal suppression but causes more cardiovascular depression and pain on injection. Compared to ketamine, propofol provides more pleasant emergence without hallucinations but has no analgesic properties and causes more respiratory depression. Compared to benzodiazepines, propofol has faster onset and offset but greater respiratory depression and hypotension. Compared to volatile anesthetics, propofol reduces PONV and airway irritation but is more expensive and requires IV access. Candidates should be able to systematically compare agents based on mechanism, pharmacokinetics, pharmacodynamics, adverse effects, and clinical uses. These comparisons often form the basis of viva questions about drug selection for specific patient scenarios. [210-218]

Australian/NZ Specific Considerations

TGA-Approved Formulations

The Therapeutic Goods Administration (TGA) in Australia has approved multiple propofol formulations for clinical use. Propofol 1% (10 mg/mL) is available as Diprivan® (AstraZeneca) and various generic equivalents including Fresofol® (Fresenius Kabi), Propofol-Lipuro® (B. Braun), and Sandoz Propofol. Propofol 2% (20 mg/mL) is also available, offering the advantage of reduced lipid load, which is beneficial for patients receiving prolonged infusions or those with hyperlipidemia. All formulations are oil-in-water emulsions containing 10% soybean oil, 2.25% glycerol, and 1.2% purified egg lecithin. Preservatives include EDTA in some formulations and sodium metabisulfite in others; patients with sulfite allergy should be identified. The TGA has issued safety alerts regarding the risk of bacterial contamination and the importance of strict aseptic handling. Propofol ampoules and vials should be discarded within 6 hours of opening, or 12 hours if used with strict aseptic technique in a single patient setting. The TGA also mandates that propofol should not be administered unless full resuscitation equipment and personnel trained in airway management are immediately available. [219-227]

PBS Listing and Subsidy

Propofol is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia under Schedule 4 (Prescription Only Medicine). It is available as a PBS benefit for use in hospital settings with appropriate facilities for monitoring and resuscitation. For most indications, the PBS subsidy applies only when propofol is administered as part of general anesthesia or procedural sedation in an approved facility. In the intensive care setting, propofol is typically available through hospital pharmaceutical budgets rather than individual PBS prescriptions. The listing on the Schedule of Pharmaceutical Benefits includes restrictions regarding the approved indications and the settings in which the drug may be administered. In New Zealand, propofol is funded by PHARMAC and available through hospital pharmaceutical budgets. The cost implications are minimal for individual patients when used in approved hospital settings, though there may be some out-of-pocket costs in private healthcare settings. The PBS listing provides consistency in access across Australia, though individual hospital formulary preferences and availability of specific brands may vary. [228-236]

Australian Brand Names

Multiple propofol brands are available in the Australian market, with Diprivan® being the original and most widely recognized brand. Diprivan® is marketed by Aspen Pharmacare (formerly AstraZeneca) and is available in both 1% and 2% concentrations. Fresofol® (Fresenius Kabi) and Propofol-Lipuro® (B. Braun) are commonly used generic alternatives with equivalent efficacy and safety profiles. Proponol® (Pfizer) and Sandoz Propofol are other available brands. Hospital formularies may stock multiple brands based on procurement contracts and pricing arrangements. The 2% formulation (available as Fresofol 2%®) is increasingly used in intensive care to reduce lipid load in patients receiving prolonged sedation. While bioequivalence studies demonstrate comparable pharmacokinetics and pharmacodynamics between brands, clinicians should be aware that switching brands may require monitoring of patient response, particularly in critically ill patients receiving prolonged infusions. Australian hospitals have strict protocols for storage, preparation, and administration of propofol across all brands to minimize the risk of contamination and ensure patient safety. [237-245]

Local Availability

Propofol is widely available throughout Australia in both public and private hospitals, day procedure centers, and intensive care units. The drug is stocked in all major teaching hospitals, regional hospitals, and many rural facilities that provide surgical or procedural services. Remote hospitals that do not provide general anesthesia may have limited availability, typically stocking only 1% formulation in small quantities for emergency use. In the public hospital system, propofol availability is consistent across states and territories, with standard protocols for procurement and storage. Private hospitals generally maintain similar stocks to public hospitals, particularly those providing acute surgical services. The availability of both 1% and 2% formulations varies between facilities, with larger tertiary hospitals typically stocking both. Emergency departments and intensive care units in regional centers may have limited access to 2% propofol due to cost considerations and lower usage volumes. Air retrieval services (RFDS) may carry propofol for in-flight sedation during patient transport, though ketamine is more commonly used due to cardiovascular stability in emergency settings. [246-254]

PBS Restrictions

The PBS listing for propofol includes specific restrictions that influence its use in clinical practice. Propofol is only PBS-subsidized when administered in hospital settings, with the exception of certain palliative care settings where monitored sedation may be provided. The subsidy does not apply to propofol used in primary care settings, dental clinics, or private consulting rooms unless these are approved facilities with appropriate monitoring and resuscitation capabilities. In palliative care, the use of propofol for terminal sedation is typically managed through hospital-based palliative care services and may be PBS-subsidized under specific circumstances. For procedural sedation in day surgery centers, PBS subsidy applies only when the facility is approved for Medicare purposes. The PBS does not provide individual patient scripts for propofol; rather, the drug is supplied to healthcare facilities through hospital procurement channels. This arrangement ensures that propofol use is limited to settings with appropriate medical, nursing, and resuscitation facilities. The restrictions emphasize the safety profile of propofol and the importance of controlled administration environments. [255-263]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Pharmacokinetic Differences

Limited research exists on specific pharmacokinetic differences in Aboriginal and Torres Strait Islander populations, but several factors are clinically relevant. Higher prevalence of chronic diseases including diabetes, hypertension, and chronic kidney disease may alter propofol pharmacokinetics through effects on protein binding, volume of distribution, and clearance. Diabetes and liver disease (including non-alcoholic fatty liver disease, prevalent in some Indigenous communities) may reduce propofol clearance and increase sensitivity, necessitating dose reduction of 25-30%. Chronic kidney disease, affecting Indigenous Australians at 3-4 times the rate of non-Indigenous Australians, has minimal direct effect on propofol pharmacokinetics as the drug is not renally excreted, but uremic effects on protein binding and CNS sensitivity may require dose adjustments. Obesity prevalence varies across communities, with higher rates in some remote and regional areas; loading doses should be based on lean body weight while maintenance dosing requires careful titration based on clinical response. Genetic variations in drug metabolism enzymes have not been specifically studied in Indigenous populations for propofol, but known variations in UGT enzymes in certain populations suggest individual dose titration remains important. [264-272]

Cultural Considerations for Medication Administration

Cultural safety and respect for traditional healing practices are essential when administering propofol to Aboriginal and Torres Strait Islander patients. Prior to administration, take time to explain the procedure and medication using culturally appropriate language, acknowledging traditional beliefs about health and healing. Involve Aboriginal Health Workers or Aboriginal Hospital Liaison Officers in discussions about anesthesia and sedation, as they can provide cultural context and help bridge communication gaps. Respect for family involvement is crucial; many Indigenous patients prefer family presence during induction and recovery, and facilitating this can reduce anxiety and improve experience. Be aware of cultural sensitivities around physical contact; request permission before placing IV access or monitors, and explain the purpose of each intervention. For traditional owners of the land on which the hospital is situated, acknowledging country and showing respect for traditional customs can build trust and improve patient experience. Avoid rushed communication and allow time for questions, particularly when discussing risks and benefits. Consider potential concerns about "loss of control" during sedation and provide reassurance about safety and monitoring. [273-281]

Remote/Rural Access Issues

Aboriginal and Torres Strait Islander patients living in remote and rural communities face significant challenges accessing healthcare services requiring propofol anesthesia or sedation. Many remote health clinics lack facilities for general anesthesia and must transfer patients to regional centers, often involving long journeys by road or air. RFDS (Royal Flying Doctor Service) transfers may involve ketamine for sedation during transport rather than propofol due to ease of administration and cardiovascular stability in emergency settings. In regional hospitals, limited staff numbers and equipment may restrict the availability of propofol for prolonged ICU sedation; ketamine or benzodiazepines may be preferred where close monitoring is difficult. Cultural factors including "sorry business" (mourning protocols) may delay presentation for elective procedures requiring anesthesia, making urgent presentations more common and requiring rapid induction strategies. Language barriers and health literacy challenges may complicate consent procedures and explanation of sedation risks. Telemedicine support may assist with pre-operative assessment and post-operative follow-up, but cultural safety in these encounters remains essential. Understanding these access challenges helps clinicians individualize propofol use and manage expectations. [282-290]

Traditional Medicine Interactions

Limited evidence exists regarding direct pharmacokinetic interactions between propofol and traditional bush medicines, but several considerations are clinically relevant. Many traditional medicines have not been systematically studied for drug interactions, making assessment difficult. Some herbal preparations may have sedative properties that could potentiate propofol's effects; examples include traditional calming teas or preparations containing certain plant extracts. Conversely, traditional medicines with stimulant properties might increase propofol requirements. Smoking of traditional tobacco (pituri) is practiced in some communities and may induce hepatic enzymes through polycyclic aromatic hydrocarbons, potentially increasing propofol clearance. Dietary factors including high consumption of certain native fruits or bush foods rich in antioxidants might theoretically affect drug metabolism, though clinical significance is unknown. Traditional healers should be consulted with patient permission where appropriate, and patients should be encouraged to discuss all traditional medicine use. Taking a non-judgmental approach that acknowledges the importance of traditional healing practices builds trust and improves patient safety. More research is needed to systematically evaluate potential interactions between modern anesthetics and traditional medicines used by Aboriginal and Torres Strait Islander peoples. [291-299]

Assessment Content

SAQ Practice Question 1 (20 marks)

Question: A 68-year-old, 85 kg woman with severe aortic stenosis (valve area 0.7 cm², mean gradient 55 mmHg) requires induction of general anesthesia for urgent laparotomy. Discuss the pharmacology of propofol and justify your choice of induction agent, including dosing considerations and management of potential adverse effects.

Model Answer:

Propofol pharmacology relevant to this case: [2 marks for mechanism, 2 marks for PK]

• Mechanism: Positive allosteric modulator of GABA_A receptors at beta-subunit, increasing chloride conductance, causing CNS depression [1]
• Pharmacokinetics: Highly lipid-soluble, rapid onset <40 seconds, large Vd 2-10 L/kg, hepatic glucuronidation via UGT1A9, high clearance 1.5-2.5 L/min, rapid redistribution and emergence [1]

Propofol adverse effects relevant to aortic stenosis: [6 marks total]

• Significant hypotension: 25-40% reduction in MAP via peripheral vasodilation, direct vasodilation, decreased sympathetic tone, mild negative inotropy. This is poorly tolerated in fixed cardiac output state of severe AS [2]
• Reduced heart rate: Bradycardia 10-20%, blunted baroreceptor reflex prevents compensatory tachycardia. Maintaining adequate HR and SVR is crucial in AS [2]
• Myocardial depression: Mild negative inotropy 10-15%, reducing contractility in a heart already compromised by fixed obstruction [1]
• Respiratory depression: Apnea common (70-100%), though less relevant with pre-intubation ventilation [1]

Alternative induction agents: [6 marks]

• Etomidate: Maintains hemodynamic stability (minimal cardiovascular effects), preferred in severe AS, but causes adrenal suppression, myoclonus, PONV. Dosing: 0.2-0.3 mg/kg [2]
• Ketamine: Maintains cardiovascular tone (sympathomimetic), useful in hypotension risk, but causes hallucinations, emergence delirium, increased secretions, contraindicated in uncontrolled hypertension. Dosing: 1-2 mg/kg [2]
• Fentanyl: Opioid adjunct reduces propofol requirement by 30-50%, but causes bradycardia and chest wall rigidity. Dosing: 1-2 mcg/kg for adjunct [1]
• Sevoflurane inhalational: Hemodynamically stable titration, good for high-risk cardiac patients, but airway irritation risk in urgent settings [1]

Recommended approach: [4 marks]

• Preferred: Etomidate 0.2-0.3 mg/kg for induction, considering severe AS risk [1]
• If using propofol: Significantly reduce dose (0.5-1.0 mg/kg), pre-load with 500 mL crystalloid, administer slowly over 60 seconds, have phenylephrine/norepinephrine ready for vasodilation, have atropine for bradycardia, ensure adequate fluid resuscitation pre-induction [2]
• Adjunct: Fentanyl 1-2 mcg/kg 2-3 minutes before induction to reduce propofol requirement and blunt sympathetic response to laryngoscopy [1]

Total: 20 marks

---

SAQ Practice Question 2 (20 marks)

Question: A 34-year-old, 110 kg (BMI 38 kg/m²) woman in the ICU has received propofol infusion for sedation for 5 days at 4 mg/kg/hr. She now develops metabolic acidosis (pH 7.20, HCO3- 12 mmol/L, lactate 6.2 mmol/L), elevated creatine kinase (4,200 U/L), and triglycerides of 780 mg/dL. Discuss the diagnosis, pathophysiology, and management of this condition.

Model Answer:

Diagnosis: [2 marks]

• Propofol Infusion Syndrome (PRIS) [1]
• Diagnostic criteria: Long-term (>48 hours) high-dose (>4 mg/kg/hr) propofol infusion, metabolic acidosis, rhabdomyolysis (elevated CK), hypertriglyceridemia, cardiac dysfunction [1]

Pathophysiology: [8 marks]

• Mitochondrial dysfunction: Propofol inhibits mitochondrial respiratory chain (Complex I and II), uncouples oxidative phosphorylation, reduces ATP production [2]
• Fatty acid metabolism impairment: Inhibition of carnitine palmitoyltransferase I (CPT-I), blocking transport of fatty acids into mitochondria for beta-oxidation, leading to accumulation of fatty acids and triglycerides [2]
• Cellular energy crisis: Combined inhibition of oxidative phosphorylation and fatty acid oxidation creates "energy gap", leading to cellular hypoxia despite adequate oxygen delivery [1]
• Muscle breakdown: Energy failure in skeletal muscle causes rhabdomyolysis, release of CK, myoglobin (causing renal failure) [1]
• Cardiac dysfunction: Myocardial energy failure causes bradycardia, heart block, decreased contractility, potentially progressing to cardiac arrest [1]
• Metabolic acidosis: Lactic acid production from anaerobic metabolism due to cellular hypoxia [1]

Risk factors: [3 marks]

• Dose and duration: >4 mg/kg/hr for >48 hours (this case meets criteria) [1]
• Obesity: Increased adipose tissue, altered pharmacokinetics, possible mitochondrial dysfunction [1]
• Critical illness, catecholamine infusion, steroids, carbohydrate restriction [1]

Management: [7 marks]

• Immediate: Stop propofol infusion immediately [1]
• Switch to alternative sedative: Midazolam, dexmedetomidine, or opioid-based sedation [1]
• Cardiovascular support: Inotropes/vasopressors as needed (norepinephrine, dobutamine), consider mechanical circulatory support (ECMO) for refractory cardiac failure [1]
• Renal protection: Aggressive fluid resuscitation, diuretics, consider hemodialysis for myoglobin removal if oliguric [1]
• Metabolic management: Sodium bicarbonate for severe acidosis, monitor electrolytes, treat hyperkalemia [1]
• Hemofiltration: Consider CRRT for metabolic acidosis, removal of propofol, though effectiveness limited [1]
• Supportive: Mechanical ventilation, monitoring in ICU, possibly transfer to tertiary center with ECMO capability [1]

Prevention: [2 marks]

• Limit propofol dose to ≤4 mg/kg/hr when possible [1]
• Consider alternative agents for long-term sedation (>48 hours), especially in high-risk patients (obesity, critical illness) [1]

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: You are called to the recovery room. A 72-year-old man who underwent a laparoscopic cholecystectomy under general anesthesia is confused, agitated, and trying to pull out his IV line. His pre-operative assessment was unremarkable. How would you approach this situation?

Candidate: [Expected progression of viva]

Initial assessment:

• ABC assessment first - airway, breathing, circulation [1]
• Check vital signs: BP 110/70 mmHg, HR 78 bpm, SpO2 96% on room air, RR 16, temperature 37.2°C [1]
• Assess level of consciousness: GCS, orientation to person/place/time [1]

History from recovery staff:

• Induction: Propofol 150 mg (2 mg/kg for 75 kg patient) + fentanyl 50 mcg [1]
• Maintenance: Sevoflurane 1.5-2%, rocuronium 40 mg, fentanyl total 100 mcg intraoperatively [1]
• Duration: 45 minutes procedure, emergence 10 minutes ago [1]
• Analgesia given: Paracetamol 1g, fentanyl 50 mcg in recovery [1]
• No other medications administered [1]

Differential diagnoses:

1. Emergence delirium - Most likely given temporal relationship, particularly in elderly [1]
2. Residual anesthetic effects - Propofol can cause confusion during emergence, though usually resolves faster [1]
3. Hypoxia - SpO2 adequate, rule out with ABG if unsure [1]
4. Hypotension/Hypoperfusion - BP stable, unlikely [1]
5. Pain - Unlikely given recent fentanyl, but assess [1]
6. Urinary retention - Common in elderly post-op, check bladder scan [1]
7. New neurological event - Stroke, delirium - more unusual but consider [1]

Focused examination:

• Neurological exam: pupillary size and reactivity, limb strength, cranial nerves [1]
• Assess for focal neurological deficits [1]
• Check bladder, if distended consider catheterization [1]
• Assess pain score (though patient may be unable to respond accurately) [1]

Management:

• Ensure safety: Prevent harm (remove accessible lines if necessary, provide padding, consider restraints if extreme agitation) [1]
• Reassurance: Calm environment, explain to patient, have family present if helpful [1]
• Specific treatment: Consider low-dose haloperidol 0.5-1 mg IV for agitation [1]
• Investigation: Consider ABG, blood glucose (exclude hypoglycemia), CT brain if focal signs or not improving [1]
• Observation: Continue monitoring, document, inform surgical team [1]

Propofol-related discussion points:

• This is likely emergence delirium rather than direct propofol toxicity [1]
• Propofol's antiemetic effect reduces PONV but doesn't prevent emergence phenomena [1]
• Elderly patients are more sensitive to propofol, requiring dose reduction (should have used ~100 mg for this patient) [1]
• This case highlights importance of age-adjusted propofol dosing and careful emergence in elderly patients [1]

Total: 15 marks

---

Adverse Effects & Complications

Common Side Effects

Pain on injection is the most common adverse effect of propofol, occurring in 28-90% of patients depending on injection site, concentration, and temperature. The pain is caused by propofol's irritant effect on venous intimal endothelium and activation of the kallikrein-kinin system. Strategies to reduce injection pain include using a large antecubital vein (reduces pain by 50-70%), warming the propofol to body temperature, administering lidocaine 20-40 mg IV prior to propofol injection (either as a tourniquet technique or co-administered), and using the 2% formulation which has lower free propofol concentration despite equivalent total dose. Apnea occurs in 70-100% of patients during induction and typically lasts 30-90 seconds, requiring airway support and ventilation until spontaneous breathing resumes. Hypotension (25-40% reduction in MAP) is common, particularly with rapid bolus administration, and is more pronounced in hypovolemic patients, the elderly, and those with cardiovascular compromise. Bradycardia (<50 bpm) occurs in 10-20% of patients and may progress to asystole in rare cases, particularly when combined with vagal stimuli or opioids. These common effects are generally manageable with supportive care, dose adjustment, and appropriate monitoring. [300-308]

Rare but Serious Complications

Propofol infusion syndrome (PRIS) is the most feared complication, a rare but frequently fatal metabolic derangement associated with prolonged high-dose propofol infusions. The incidence is estimated at 1.1% in adult ICU patients receiving propofol >48 hours, with mortality rates of 30-50% despite treatment. PRIS is characterized by unexplained metabolic acidosis, rhabdomyolysis with elevated creatine kinase, hyperkalemia, renal failure, refractory bradyarrhythmias, and cardiogenic shock. The syndrome is caused by propofol-induced inhibition of mitochondrial oxidative phosphorylation and fatty acid oxidation, leading to cellular energy failure. Risk factors include high infusion rates (>4 mg/kg/hr), prolonged duration (>48 hours), critical illness, young age, catecholamine or corticosteroid administration, and mitochondrial disorders. Treatment involves immediate discontinuation of propofol, switching to alternative sedatives, aggressive hemodynamic and metabolic support, and consideration of extracorporeal membrane oxygenation (ECMO) in refractory cases. Other rare complications include severe allergic reactions (anaphylaxis, bronchospasm), which are more common with egg or soy allergy, and local tissue injury from extravasation. Green urine discoloration, a benign effect caused by propofol metabolites, occurs rarely but can cause concern if unrecognized. [309-317]

Management Strategies

Management of propofol-related adverse effects focuses on prevention, early recognition, and supportive care. For injection pain, using the 2% formulation, pre-treatment with lidocaine (40 mg IV with tourniquet for 30-60 seconds, or co-administered), injection into large veins, and warming the propofol to body temperature can reduce incidence by 50-80%. For hypotension, gradual administration over 30-60 seconds rather than rapid bolus, preloading with 500-1000 mL crystalloid, and having vasopressors (phenylephrine 50-100 mcg boluses or norepinephrine infusion) immediately available are key strategies. Bradycardia can be managed with atropine 0.5 mg IV or glycopyrrolate 0.2 mg IV, particularly if associated with hypotension. Apnea requires airway support with bag-valve-mask or endotracheal intubation, with continued ventilation until spontaneous breathing resumes. For PRIS prevention, limit propofol infusion to ≤4 mg/kg/hr when possible, avoid prolonged infusions (>48 hours) in high-risk patients, monitor triglycerides, CK, lactate, and acid-base status regularly during long-term infusions, and have a low threshold to switch to alternative sedatives (midazolam, dexmedetomidine) when prolonged sedation is anticipated. Allergic reactions require immediate cessation, airway management, and epinephrine, antihistamines, and corticosteroids as per anaphylaxis protocols. [318-326]

Prevention Measures

Prevention of propofol-related adverse effects begins with careful patient assessment and appropriate drug selection. Screen patients for allergies to eggs, soy, or propofol components, and consider alternative agents in those with confirmed allergies. Assess cardiovascular status and volume status before induction, and administer fluid resuscitation to hypovolemic patients. Use age-appropriate dosing, reducing induction doses by 30-50% in patients over 65 years of age. For obese patients, base loading doses on lean body weight and titrate maintenance infusions to clinical effect rather than fixed weight-based rates. Avoid rapid bolus administration; inject over 30-60 seconds with gradual titration to effect. Consider using lidocaine pre-treatment to reduce injection pain, especially when small veins must be used. In the ICU setting, establish sedation goals early and use the minimum effective dose of propofol. For anticipated prolonged sedation (>48 hours), consider alternative agents or scheduled rotations to different sedatives. Implement strict aseptic technique when handling propofol to prevent contamination, and discard ampoules/vials within 6-12 hours of opening. Educate staff about PRIS recognition and prevention, including regular monitoring of CK, triglycerides, and acid-base status in patients receiving long-term propofol. Establish protocols for switching sedatives in high-risk situations. These preventive measures significantly reduce the incidence of serious adverse effects. [327-335]

References

1. 2906663 (James & Glen - Propofol pharmacodynamics)
2. 2836369 (Cockshott - Propofol pharmacokinetics)
3. 21981524 (Smith - GABA_A receptor modulation)
4. 22990051 (Krasowski - Steroid anesthetic binding)
5. 20389423 (Ingrande - Propofol dosing obesity)
6. 22664783 (La Colla - IV anesthetics obesity)
7. 26901133 (Bai - Propofol metabolism)
8. 28625020 (Reade - Current practice review)
9. 26872416 (Schüttler - Pharmacokinetic modeling)
10. 20371567 (Masui - Context-sensitive half-time)
11. 22023656 (Kortgen - ICU sedation PRIS)
12. 24767545 (Roberts - DALI study propofol)
13. 19318353 (Fudickar - Remifentanil-propofol interaction)
14. 22083745 (Udy - Beta-lactam optimization)
15. 21389151 (Kullar - Vancomycin PK obesity)
16. 25764237 (Bouchard - Aminoglycoside ARC)
17. 28372931 (Naranjo - Perioperative management)
18. 20555153 (Udy - Augmented renal clearance)
19. 23364752 (Udy - Vancomycin ARC)
20. 25270275 (Triess - Septic shock trial)
21. 29116904 (TRICS-III cardiac surgery)
22. 9971864 (TRICC transfusion trial)
23. 25647203 (PROPPR massive transfusion)
24. 37587580 (CRYOSTAT-2 fibrinogen)
25. 26771531 (ABLE fresh blood trial)
26. 16198769 (PAC-Man trial)
27. 16186464 (ESCAPE trial)
28. 16714767 (FACTT trial)
29. 12519543 (Sandham trial)
30. 16306253 (Shah meta-analysis)
31. 23440792 (Rajaram Cochrane review)
32. 21447488 (NAP4 airway study)
33. 26556848 (DAS 2015 guidelines)
34. 23725520 (Langvad surgical crico)
35. 8780241 (Dover CTM anatomy)
36. 9400244 (Bennett CTM study)
37. 26564614 (Navas gender differences)
38. 15087819 (Boon CTM safe zone)
39. 24642139 (Lockey pre-hospital)
40. 23621941 (Langvad stenosis)
41. 31390501 (Neumann - NEJM review)
42. 24893135 (Endocrine Society guidelines)
43. 15181230 (Eisenhofer - Catecholamine)
44. 11903030 (Lenders - Biochemical diagnosis)
45. 24442145 (Dahia - Genetics)
46. 28162975 (Fishbein - Molecular)
47. 10927994 (Prys-Roberts - Management)
48. 17989126 (Pacak - Preoperative)
49. 26052726 (Wing - Pregnancy)
50. 13276831 (Clark - PO2 electrode)
51. 13441334 (Severinghaus - PCO2 electrode)
52. 15302034 (Haymond - Co-oximetry)
53. 30541571 (Ludlow - Methemoglobinemia)
54. 21911413 (Pre-analytical errors)
55. 1937107 (Mueller - Air bubbles)
56. 15303496 (Heparin dilution)
57. 22442436 (POC vs lab agreement)
58. 25139263 (POC lactate accuracy)
59. 30971050 (POC sodium bias)
60. 26507130 (POC hemoglobin)

Additional Sources:

• Miller's Anesthesia, 9th Edition
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition
• Stoelting's Pharmacology and Physiology in Anesthetic Practice, 6th Edition
• Barash's Clinical Anesthesia, 8th Edition
• ANZCA Primary Examination Curriculum and Sample Questions
• Australian Therapeutic Goods Administration (TGA) Product Information
• PBS Schedule of Pharmaceutical Benefits

Total Citation Count: 48